Skip to main content
SpringerLink
Log in

Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Prostate carcinoma is the most frequently diagnosed malignancy and the second leading cause of death as a result of cancer in men in the US and other parts of the world. There are conflicting reports on the serum levels of testosterone and 17β-estradiol (E2) in benign prostatic hyperplasia (BPH) and prostate cancer. This study was designed to evaluate the serum concentrations of these hormones in patients with these disorders. Serum levels of prostate specific antigen (PSA), total testosterone and estradiol were determined in 228 subjects comprising of 116 subjects with BPH, 62 subjects with prostate cancer (CaP) and 50 age-matched apparently healthy controls, using ELISA methods. PSA levels were significantly elevated (p < 0.05) in BPH subjects than controls, while there was no significant difference (p > 0.05) in testosterone and estradiol levels of these subjects. PSA and estradiol levels were significantly higher (p < 0.05) in CaP subjects than in controls, while there was no observed significant difference (p > 0.05) in testosterone levels. CaP subjects had significantly raised PSA, testosterone, and estradiol levels than BPH subjects. The mean molar ratio of testosterone: E2 was lowest among CaP patients (134:1) and highest among controls (166:1). Significant positive correlation between PSA and 17β-estradiol was observed in prostate disorders (BPH and CaP patients: r = 0.347; p = 0.000). Significant negative correlations between testosterone and PSA were also observed among BPH patients (r = −0.221, p = 0.049) and control subjects (r = −0.490, p = 0.000). No significant correlation existed between testosterone and PSA in CaP patients (r = 0.051, p = 0.693). Correlations between age and estradiol in both BPH and CaP were not significant (p > 0.05). This study has shown that, there was a significant increase in serum estradiol in CaP subjects, while the testosterone levels in both BPH and CaP subjects were not different from those of controls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. Cancer J Clin. 2005;55(1):10–30.

    Article  Google Scholar 

  2. Hsing AW, Anand P, Chokkalingam C. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–413.

    Article  CAS  PubMed  Google Scholar 

  3. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high risk cohorts. Eur Urol. 1999;53:360–2.

    Google Scholar 

  4. Boyle P, Seven G, Giles GG. The epidemiology of prostate cancer. N Am J. 2003;30:207–10.

    Google Scholar 

  5. Ogunbiyi JO, Shittu OB. Increased incidence of prostate Cancer in Nigerians. J Natl Med Assoc. 1999;90(3):159–64.

    Google Scholar 

  6. Nkposong EO, Lawani J. Primary carcinoma of the prostate in Ibadan. West Afr Med J. 1973;22:108–11.

    CAS  Google Scholar 

  7. Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the south-Eastern states. J Natl Med Assoc. 2002;94(7):619–27.

    PubMed Central  PubMed  Google Scholar 

  8. Angwafo FF. Migration and prostatic cancer: an international perspective. J Natl Med Assoc. 1998;90:5720–3.

    Google Scholar 

  9. Olapade-Olaopa EO, Ahiaku E. ‘The changing face’ of prostatic carcinoma in Black Africans. The view at the, 1995 Pan African Urological Surgeons Association meeting. Cancer Topics. 1995;10:4–7.

    Google Scholar 

  10. Bosland MC. Hormonal factors in carcinogenesis of the prostate and testis in humans and animal models. In: Huff J, Boyd J, Barett JC, editors. Cellular and molecular mechanisms of hormonal carcinogenesis. Environmental influences. New York: Wiley-Liss; 1996. p. 309–52.

    Google Scholar 

  11. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002;52:213–35.

    Article  CAS  PubMed  Google Scholar 

  12. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol. 2000;10:415–20.

    Article  CAS  PubMed  Google Scholar 

  13. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study on aging. J Clin Endocrinol Metab. 2001;86:724–31.

    Article  CAS  PubMed  Google Scholar 

  14. Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among men with a prostate specific antigen level < or = 4.0 ng/ml. N Engl J Med. 2004;350:2239–40.

    Article  CAS  PubMed  Google Scholar 

  15. Fowler JE Jr, Whitemore WF Jr. The response of metastatic adenocarcinomas of the prostate to exogenous testosterone. J Urol. 1981;126:370–2.

    Google Scholar 

  16. Mearini L, Constantini E, Zurchi A, Mearini E, Bini V, Cottini E, Porena M. Testosterone levels in benign prostatic hyperplasia and prostate cancer. Urol Int. 2008;12:134–40.

    Article  Google Scholar 

  17. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafson JA. Cloning of a novel receptor expressed in rat prostate and ovary. PNAS. 1996;93:5925–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Wong YC, Wang YZ. Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol. 2000;12:199–265.

    Google Scholar 

  19. McConnel JD. The long-term effect of Doxazosin, Finasteride and combination therapy on clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–90.

    Article  Google Scholar 

  20. Gann PH, Hennekens CH, Ma J, Loongcope C, Stampfer MJ. Prospective study of sex hormones levels and risk of prostate cancer. J Am Natl Cancer Inst. 1996;88(16):1118–26.

    Article  CAS  Google Scholar 

  21. Platz EA, Rimm EB, Willet WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professional. J Am Natl Cancer Inst. 2005;92:2009–17.

    Article  Google Scholar 

  22. Stattin P, Lumme S, Tenkanen L. Levels of circulating testosterone are not associated with increased prostate cancer risks: a pooled prospective study. Int J Cancer. 2004;108:418–24.

    Article  CAS  PubMed  Google Scholar 

  23. Griffiths K. Estrogens and prostatic disease. International Prostate Health Council Study Group. Prostate. 2000;45:87–100.

    Article  CAS  PubMed  Google Scholar 

  24. Walsh PC, Hutchins GM, Ewing LL. The tissue content of DHT in human prostatic hyperplasia is not supranormal. J Clin Invest. 1983;72:1772–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Taplin ME, Ho SM. Clinical review 134: the endocrinology of prostate cancer. J Clin Endocrinol Metab. 2001;86:3467–77.

    Article  CAS  PubMed  Google Scholar 

  26. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000;27:39–66.

    Article  CAS  PubMed  Google Scholar 

  27. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76:45–8.

    CAS  PubMed  Google Scholar 

  28. de Jong FH, Oishi K, Hayes RB, Bogdanowicz JF, Raatgever JW, van der Maas PJ, Yoshida O, Schroeder FH. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case–control study. Cancer Res. 1991;51:3445–50.

    PubMed  Google Scholar 

  29. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor α signaling. FASEB J. 2008;22:1512–20.

    Article  CAS  PubMed  Google Scholar 

  30. Nanni S, Narducci M, Della Pietra L, Moretti F, Grasselli A, De Carli P, Sacchi A, Pontecorvi A, Farsetti A. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest. 2002;110:219–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Risbridger GP, Wang H, Frydenberg M, Cunha G. The metaplastic effects of estrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. Endocrinology. 2001;142:2443–50.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Pathology, College of Health Sciences, University of Uyo, Uyo, Nigeria

    Anthony J. Usoro & Itemobong S. Ekaidem

  2. Department of Chemical Pathology, College of Medical Sciences, University of Calabar, Calabar, Nigeria

    Alphonsus E. Udoh

  3. Endocrinology/Research Unit, Chemical Pathology Laboratory, University of Uyo Teaching Hospital, Uyo, Nigeria

    Aniebietabasi S. Obot

  4. Department of Surgery, College of Health Sciences, University of Uyo, Uyo, Nigeria

    Okon E. Akaiso

  5. Oxidative Stress Research Centre, Department of Biomedical Sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, 7535, South Africa

    O. Akinloye

Authors
  1. Anthony J. Usoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aniebietabasi S. Obot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Itemobong S. Ekaidem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Okon E. Akaiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alphonsus E. Udoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O. Akinloye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Itemobong S. Ekaidem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Usoro, A.J., Obot, A.S., Ekaidem, I.S. et al. Serum Testosterone, 17β-Estradiol and PSA Levels in Subjects with Prostate Disorders. Ind J Clin Biochem 30, 59–65 (2015). https://doi.org/10.1007/s12291-013-0411-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-013-0411-3

Keywords

Search

Navigation